a purification device according to the invention has , as shown in fig1 , an extracorporeal blood circulation loop comprising a removal line 1 , means for circulation and for control of blood flow rate 11 , such as a pump , to remove the blood from the body of the patient p , a return line 3 to bring the purified blood back into the body of the patient p , and blood purification means 5 that are placed between an intermediate line 2 connected to the blood circulation means 11 downstream from the latter and the return line 3 and that consist of , for example , filters , dialyzers or adsorption cartridges . means 4 making it possible to inject a fluid containing citrate ( ci ) are placed on the blood circulation loop 1 , 11 , 2 , 3 . these means 4 comprise a bag 4 ′ containing the fluid to be injected , a line 4 ″ connecting the bag 4 ′ to the removal line 1 or to the intermediate line 2 , and a pump 40 making it possible to inject the contents of the bag 4 ′ into the removal line 1 or the intermediate line 2 by way of the line 4 ″. optionally , the device can be completed by means 6 making it possible to inject calcium ( ca ) and / or magnesium ( mg ) ( either by a single element as shown or by separate elements — one for calcium and the other for magnesium ) into the return line 3 , and by treatment means 7 , 8 , 9 , 10 making it possible to perform the known purification techniques . the means for injecting the calcium / magnesium 6 can comprise in particular a line 6 ″ connecting a bag 6 ′ containing a solution comprising calcium and / or magnesium to the removal line 3 and a pump 60 for the injection of the contents of the bag into the circulation loop . in fig1 , the reference 9 designates in particular means for injecting a dialyzate comprising a dedicated line 9 ″ connected to the blood purification means 5 , a dialyzate bag 9 ′ and a pump 90 ; the reference 8 designates means for removing the contaminated solution comprising in particular a removal line 8 ″ connected to the blood purification means 5 , a bag for the contaminated liquid 8 ′ and a removal pump 80 ; the reference 7 designates means for injecting post - dilution replacement liquid comprising a post - dilution line 7 ″ connected to the removal line 3 , a post - dilution pump 70 , and a post - dilution bag 7 ; and the reference 10 designates means for injecting a pre - dilution liquid comprising a line 10 ″ connected to the intermediate line 2 , for example , a pre - dilution bag 10 ′ and a pre - dilution pump 100 . the dialyzate injection means 9 and the contaminated solution removal means 8 make it possible in particular to perform a hemodialysis . the pre - dilution means 10 , the contaminated solution removal means 8 , and the post - dilution means 7 make it possible to perform a hemofiltration , and the dialyzate injection means 9 , the contaminated solution removal means 8 , the post - dilution means 7 and / or the pre - dilution means 10 make it possible to perform a hemodiafiltration . the blood loop 1 , 2 , 3 can be completed in practice by the means that are customary but not shown for protection of the circuit , such as , for example , pressure sensors , or for protection of the patient , such as , for example , a blood leak detector or an air detector associated with a clamp . these means are widely known to a person skilled in the art and are described in the literature . means for circulation and for flow rate control other than the pumps 11 , 40 , 100 , 90 , 80 , 70 and 60 mentioned above exist ( for example , clamps ) and are described in the literature and can obviously be used in this invention instead of said pumps . the device according to the invention has in addition a control unit 20 shown in fig2 and comprising in particular a user interface 21 , a calculating unit 22 , a memory 23 , and control means 24 connected to each of the means for circulation and for flow rate 11 , 40 , 60 , 70 , 80 , 90 , 100 present on the blood circulation loop 1 , 2 , 3 , 4 and making it possible to control said means for circulation and for flow rate . according to the invention , the control unit 20 is programmed to force the user to insert , by way of the user interface 21 , at least one established parameter as being a representative value and that makes possible the checking of the adequacy of the treatment and anticoagulation values , at a time interval that is determined according to pre - established rules and placed in the memory 23 . according to the models used for the treatment , the representative value can be , for example , the level of ionized calcium at a point of the blood circulation loop 1 , 2 , 3 , 4 , the ph of the patient or his total calcium , and all other values that are known to be representative in the model under consideration . hereinafter , the expression “ representative value ” designates any one of these values and / or any combination or set of these values . the user interface 21 also makes possible the entry by the user of the treatment and anticoagulation values and the display of messages necessary for the proper implementation of the treatment . the calculating unit 22 verifies the required treatment and anticoagulation parameters , i . e ., the flow rates of the circulation means 40 , 60 , 70 , 80 , 90 , 100 , 11 , or of some of them , as a function of the pre - established rules and of the representative value previously entered by the user , and sends to the user interface the messages necessary for updating the treatment . if the required values are acceptable for the calculating unit 22 , it then sends the corresponding orders to the control means 24 of the fluid circulation means 40 , 60 , 70 , 80 , 90 , 100 , 11 , or some of them . the pre - established rules rely on known equations but can also incorporate new conditions , particularly high and low limits . among the known equations , there can particularly be cited the fact that to each fluid , a flow rate “ q ” corresponds that is represented by way of example by the pump ( s ) 40 , 60 , 70 , 80 , 90 , 100 , 11 . for each substance contained in a fluid , the amount injected “ m ” in terms of unit of time “ t ” is provided by the product of the concentration “ c ” with the corresponding flow rate or : m = q * c . since the flow rates and the concentrations are known by the device , either because they are entered by way of the user interface 21 or because they are automatically calculated by the calculating unit 22 , it is possible to calculate the masses of the substances that interest us , particularly those of the citrate and of the calcium , and to deduce from them acceptance values by applying additional rules such as , for example , the balance between calcium that is injected and lost in the circuit or the maximum admissible citrate mass . the flow rate and concentration values that must be calculated are in accordance with the rules known to a person skilled in the art . to illustrate this with the example of a hemofiltration treatment , the operator supplies a post - dilution substitution flow rate used to control the pump 70 and a weight loss flow rate ; the calculated discharge flow rate of the pump 80 is then equal to the sum of the substitution flow rate and of the weight loss so as to remove weight ( in this particular case mainly in the form of water ) from the patient in accordance with the instruction of the operator . another example would be the case of the calculation of the concentration of citrate in the blood that is circulating in the purification means 5 ( cci 5 ), considering that the pre - dilution pump 100 is stopped and therefore does not affect the calculation . in this case , the concentration would be calculated from that in the bag 4 ′ ( cci 4 ), of fluid containing citrate , and flow rates of citrate qci and of blood qb with : cci 5 = cci 4 *( qci /( qb + qci )). thus , for each point of the circulation loop 1 , 2 , 3 shown in fig1 , the flow rates and concentrations of the substances that interest us can be known , either because they are entered by way of the interface 21 by the operator or by calculation . the detailed calculations that can be applied to this invention in their complete form or another simplified form have already been the object of publications ( see kozik - jaromin , citrate kinetics during regional citrate anticoagulation in extracorporeal organ replacement therapy , aus des medizinischen universitätklinik abteilung innere medizin iv ( nephrologie ˜ 1 allgemeinmedizin ) der albert - ludwigs - universität freiburg i . br ., 2005 ) and patents us 2011 / 0288464 and us 2011 / 0168614 . to make the treatment safer , other rules must also be applied , particularly those that define the limit values of citrate . actually , on the one hand , the patient cannot tolerate without unwanted secondary effects an injection of citrate beyond an established value , at 80 mg / kg / h in the literature , or involving a ph greater than 7 . 45 and , on the other hand , a value that is too low that would increase the risk of coagulation in the loop . because of an incomplete model that means that since the citrate is bonding to the calcium and to the magnesium , the more blood there is , the more calcium and magnesium there is with which to bind , and therefore the more citrate is necessary to maintain the targeted value of calcium and the coagulation time , the flow rate of citrate is often defined as a ratio of the blood flow rate . the problem at a high blood flow rate is that too much citrate is injected relative to what the patient can tolerate and to what is useful since , with the time in the circuit diminishing when the blood flow rate increases , the anticoagulation can be less at a high blood flow rate . conversely , at a low blood flow rate , the time in the circuit is long and at a proportional citrate flow rate , therefore constant anticoagulation , the risk of coagulation in the loop increases even though the injected citrate is far below the acceptable limit value for the patient . in this case , there would therefore be interest in injecting proportionally more citrate into the blood so as to increase the coagulation time . thus , the device according to the invention can incorporate rules and values that restrict the mass of citrate injected , upward as a function of the tolerance of the patient and downward as a function of the coagulation time that is necessary to ensure that the blood travels through the circulation loop 1 , 2 , 3 . to the rules of evaluation described above , a device according to the invention adds rules for acceptance of the parameters entered by the operator by way of the interface 21 . these rules of acceptance can depend or not upon the representative parameter of the anticoagulation . for example , a high citrate ratio with a high blood flow rate resulting in an injection known to be dangerous for the patient can be rejected , an upper limit of a citrate ratio then being able to be proposed . another example is that if the representative parameter is , for example , the ionized calcium of the patient , and the value entered shows a value known to be low , for example less than 1 . 1 mmol / l , the device can reject that the injection of calcium by the pump 60 be reduced , or not accept it until after a double validation by the operator . the rules of acceptance can contain , as a function of the circumstances , one or more optimal value ( s ) and an associated margin of tolerance . it is quickly understood that the possibility exists of creating numerous rules of acceptance and that these are called upon to change with the knowledge of the doctor . a device according to the invention can thus use any rule aiming to reduce the risks described previously for the patient . the device according to the invention operates overall as shown by way of example in fig3 , knowing that numerous algorithm variants meeting the same need are possible . the device asks the operator by way of the user interface 21 to enter the treatment data and the representative value ( s ) of the treatment at a given time . the calculating unit then uses the applicable rules and values placed in the memory 23 to verify if the data entered are acceptable . if this is the case , the calculating unit 22 sends the information to the means for controlling the pumps 24 that then feed the latter to produce the flow rates that are requested or calculated . if this is not the case , the calculating unit 22 verifies first whether the deviation is at this point significant enough that a doctor must be called , in which case it can inform the user interface 21 of it which will display a message indicating the necessity of a check by the doctor and will stop the treatment if it is underway , that is to say that it will indicate to the control means 24 to send a zero instruction to the pumps 70 , 80 , 90 , 100 and depending on the cases 40 and / or 60 . otherwise , the device requests that the values of treatments be adjusted while respecting the applicable rules of acceptance . when the treatment values have been adjusted and are acceptable , the treatment can continue , the next time interval for the following check being reevaluated . once this has elapsed , the device again requests entering the representative value ( s ) and recommences its acceptance cycle . the reevaluation of the time interval is necessary , on the one hand , to ensure the safety of the patient and , on the other hand , to minimize the number of measurements of the representative values that necessitate time , funding , and most often blood samples . it is defined by rules and reference values stored in the memory 23 . for example , at the beginning of the treatment , the interval is equal to a half - hour the first hour , then one hour for the following hour , then every four hours until twenty - four hours of treatment , then every twelve hours . this set program can be modulated , for example after a significant change defined as being a variation of at least 30 % of one of the treatment parameters ; it is conceivable to come back to a time interval of one hour before going again to four , then to twelve hours . in the same way , this time interval can also be modified as a function of the values received with — for example if the calcium measured is beyond a known limit that would be used to warn the doctor — a return to two measurements made every half - hour before continuing with intervals at one , four and twelve hours . the values supplied above are by way of illustration of the remarks , and the device according to the invention makes it possible as a variant that they can be modified , for example , as a technical parameter adjusted to the delivery of the device as a function of the requirements of the center that will use the device , or as parameters linked to the definition of the treatment or as parameters modified by the operator during treatment to lengthen or shorten the predetermined interval , as a function of his own knowledge . the values entered at these intervals determined by the device are used by the acceptance rules of the treatment values . as entered value ( s ), it is possible to consider , by way of example , the ionized calcium of the patient , its ratio with the total calcium , the ionized calcium as input and / or output of the purification means 5 or else the ph of the patient . by incorporating these values into the calculation rules , the calculating unit 22 can then determine , on the one hand , if the treatment parameters are within acceptable ranges and , on the other hand , the time interval for the next check as well as the messages to be displayed . the device thus makes it possible to warn of the entry of treatment values that can lead to imbalances and therefore risks for the patient or of coagulation of the blood in the circulation loop 1 , 2 , 3 . an essential advantage of this invention lies in the fact that it makes it possible , relative to existing devices , to significantly reduce the risks connected to the use of citrate as an anticoagulant , the operator having the obligation at determined intervals of time to insert one or more determining values for the rules of acceptance . also , it makes it possible to vary safely the treatment parameters while helping the health care providers and while limiting the risks and the range of potential errors . of course , the variant embodiments according to the invention comprise the various known extracorporeal purification circuit configurations but also the possibility of using different solutes comprising citrate and calcium and injecting them at different locations of the circuit . for example , the pre - dilution solution contained in the bag 10 ′ can contain the citrate used as anticoagulant , or the dialyzate contained in the bag 9 ′ can contain the calcium used to restore the calcium level of the patient . as another example , the solute containing citrate can use any formula of sodium citrate or of citrate - dextrose ( acd ), whereas calcium is injected in the concentrated form of calcium chloride or calcium gluconate or with a physiological concentration contained in the dialyzate or the substitution liquid . the concentrations of citrate and calcium can obviously vary from one fluid to the next and therefore will have to be entered by way of the user interface 21 so that the masses that are injected and rejected from the circulation loop 1 , 2 , 3 can be evaluated by the calculating unit 22 . other electrolytes can also be considered in the model , particularly sodium injected with citrate in the case of using sodium citrate or chlorine mixed with the calcium solution . actually , a hypernatremia , resulting from a significant injection of sodium , can cause serious brain lesions by tearing the meningeal vessels , whereas chlorine is itself a major element affecting the determination of the ph . also , the presence of magnesium in the solutes injected into the circulation loop 1 , 2 , 3 can be taken into consideration since magnesium binds to citrate and reduces accordingly the capacity of the latter to bind to calcium .
a device for purifying blood includes an extracorporeal blood circulation loop , flow rate control elements to manage the blood circulation in the extracorporeal blood circulation loop , blood purification elements configured on the extracorporeal blood circulation loop , citrate injection elements for injecting a solution including citrate into the extracorporeal blood circulation loop , and a control unit configured to control the citrate injection elements and the flow rate control elements . the control unit is further configured to require , at determined time intervals of a blood purification treatment used by the device , the entry of at least one representative value of the status of the device and / or of the patient . the control unit then verifies the adequacy of the representative value with pre - established rules stored in the control unit and controls the citrate injection elements and / or the flow rate control elements in accordance with the result of the verification and the pre - established rules .